TITANBIO.BO · BSE
TITAN BIOTECH LTD.
₹410.65
+1.50% (+₹6.05)
Prev. close
₹404.6
Volume
9,623
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About TITAN BIOTECH LTD.
Titan Biotech Limited engages in the manufacture and sale of biological products in India and internationally. It offers food ingredients, including hydrolyzed vegetable protein, yeast extract powder, calcium propionate powder, potassium sorbate, and calcium lactate; collagen and protein products, such as wheat hydrolysate protein, corn hydrolysate protein, bovine collagen peptide, collagen peptide, fish collage, undernatured chicken collagen type II, mucopolysaccharides, chicken protein isolate, soya protein isolate, and pea protein isolate; and brown rice protein, milk protein, protein hydrolysate, bovine cartilage extract, L-glutathione, cow colostrum powder, collagen peptides, whey protein, sodium caseinate, chondroitin sulphate, and hyaluronic acid. The company also provides coenzyme Q10, glucosamine KCL/HCL, methyl sulfonyl methane, chelated minerals, and peptone; OX bile extract, cholic acid, cerebroprotein hydrolysate, and iron protein succinylate; medicinal yeast and brewer yeast protein; and animal nutrition comprising mannan oligosaccharide, amino chelated mineral, sodium and calcium butyrate, sodium and calcium propionate, protein hydrolysate, and active dry yeast. In addition, it offers liver, meat, malt, and yeast extract. Its products are used in the pharmaceuticals, nutraceuticals, food and beverages, biotechnology and fermentation, cosmetics, veterinary and animal feed, agriculture industries, and microbiology and plant tissue culture media fields. The company also exports its products. Titan Biotech Limited was incorporated in 1992 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Naresh Kumar Singla
Headquarters
New Delhi
Employees
527
Website
titanbiotechltd.comExchange
View on BSE ↗Key stats
Market cap
₹1,696.74 Cr
P/E ratio (TTM)
263.2
Dividend yield
0.12%
EPS (TTM)
₹1.56
Beta (1Y · daily vs NIFTY 50)
0.05
Beta (5Y · monthly vs NIFTY 50)
-0.75
Shares float
1.31 Cr
EPS · quarter ended Jun 2026
₹2.63
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹142.24 Cr | ₹152.81 Cr | ₹144.00 Cr | ₹164.07 Cr | ₹156.45 Cr | ₹206.19 Cr | |
| EBITDA | ₹46.59 Cr | ₹42.02 Cr | ₹31.28 Cr | ₹35.80 Cr | ₹29.12 Cr | ₹43.84 Cr |
| ₹31.71 Cr | ₹28.74 Cr | ₹24.84 Cr | ₹24.85 Cr | ₹21.53 Cr | ₹29.89 Cr | |
| Diluted EPS | ₹7.34 | ₹6.13 | ₹6.01 | ₹6.01 | ₹5.21 | ₹7.23 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹134.52 Cr | ₹157.03 Cr | ₹174.71 Cr | ₹213.88 Cr | |
| — | — | ₹8.51 Cr | ₹8.30 Cr | ₹2.80 Cr | ₹5.71 Cr | |
| Stockholders' equity | — | — | ₹109.91 Cr | ₹133.45 Cr | ₹153.40 Cr | ₹181.55 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹21.18 Cr | ₹21.15 Cr | ₹20.12 Cr | ₹30.42 Cr | |
| Investing cash flow | — | — | ₹-20.73 Cr | ₹-20.30 Cr | ₹-9.85 Cr | ₹-32.55 Cr |
| — | — | ₹-2.40 Cr | ₹-2.87 Cr | ₹-7.98 Cr | ₹-1.53 Cr | |
| Capital expenditure | — | — | ₹-13.46 Cr | ₹-19.69 Cr | ₹-8.57 Cr | ₹-7.43 Cr |
| End cash position | — | — | ₹4.86 Cr | ₹2.84 Cr | ₹5.13 Cr | ₹1.48 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| TITAN BIOTECH LTD. | ₹1,671.75 Cr | ₹407.15 | 261.0 | 9.21 | 16.5% | 0.03 | +31.8% | -54.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 25
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Titan Biotech jumps 5% on 1:4 bonus issue, dividend announcements
Business Standard · 18 days ago
Titan Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2026
marketscreener.com · 1 month ago